Blackstone revs up Autolus’ CAR with $250m fuel injection
acute lymphoblastic leukaemia, Autolus, Blackstone, CAR-T therapies, cell therapy, financing, immuno-oncology, Oncology
0 Comment
Autolus
Autolus’ solid tumour CAR-Ts will have ‘off switch’
Up and coming immunotherapy company Autolus has published details of an ‘off switch’ safety features in its next generation CAR-Ts.
How can the UK improve in clinical research? A biotech perspective
Autolus, Biotech, European biotech, MHRA, UK biotech
0 Comment
The UK is a great place for early-stage research – but NHS red tape and market access remain major barriers.